Home » Stocks » Precision BioSciences

Precision BioSciences, Inc. (DTIL)

Stock Price: $6.98 USD 0.13 (1.90%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 365.37M
Revenue (ttm) 19.46M
Net Income (ttm) -101.20M
Shares Out 52.34M
EPS (ttm) -1.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $6.98
Previous Close $6.85
Change ($) 0.13
Change (%) 1.90%
Day's Open 6.89
Day's Range 6.72 - 7.00
Day's Volume 314,838
52-Week Range 4.46 - 23.67

More Stats

Market Cap 365.37M
Enterprise Value 249.40M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 52.34M
Float 38.47M
EPS (basic) -1.92
EPS (diluted) -1.98
FCF / Share -1.94
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.81M
Short Ratio 3.24
Short % of Float 7.30%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 18.77
PB Ratio 4.27
Revenue 19.46M
Operating Income -104.14M
Net Income -101.20M
Free Cash Flow -100.58M
Net Cash 115.97M
Net Cash / Share 2.22
Gross Margin 114.26%
Operating Margin -535.08%
Profit Margin -519.90%
FCF Margin -516.77%
ROA -28.54%
ROE -77.97%
ROIC -303.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(151.72% upside)
Current: $6.98
Target: 17.57
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth104.34%67.84%-
Gross Profit22.2410.886.48
Operating Income-87.20-47.91-21.97
Net Income-92.88-46.04-21.10
Shares Outstanding41.9915.7815.91
Earnings Per Share-2.21-2.92-1.33
Operating Cash Flow-71.02-51.72-24.17
Capital Expenditures-24.67-15.66-5.52
Free Cash Flow-95.68-67.39-29.68
Cash & Equivalents18110362.80
Net Cash / Debt18110362.80
Book Value13839.96-26.37
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Precision BioSciences, Inc.
Country United States
Employees 220
CEO Matthew R. Kane

Stock Information

Ticker Symbol DTIL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DTIL
IPO Date March 28, 2019


Precision BioSciences operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20AL, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma. The Food segment develops food and nutrition products. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.